Cim Investment Management Inc. Decreases Stock Position in Merck & Co., Inc. (NYSE:MRK)

Cim Investment Management Inc. cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,804 shares of the company’s stock after selling 402 shares during the period. Cim Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $1,385,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Resources Management Corp CT ADV grew its holdings in Merck & Co., Inc. by 0.7% during the first quarter. Resources Management Corp CT ADV now owns 17,775 shares of the company’s stock worth $1,370,000 after acquiring an additional 132 shares during the period. Oxler Private Wealth LLC grew its holdings in Merck & Co., Inc. by 1.8% during the second quarter. Oxler Private Wealth LLC now owns 7,332 shares of the company’s stock worth $570,000 after acquiring an additional 132 shares during the period. Rice Partnership LLC grew its holdings in Merck & Co., Inc. by 3.6% during the second quarter. Rice Partnership LLC now owns 3,826 shares of the company’s stock worth $298,000 after acquiring an additional 133 shares during the period. Well Done LLC grew its holdings in Merck & Co., Inc. by 4.0% during the second quarter. Well Done LLC now owns 3,508 shares of the company’s stock worth $273,000 after acquiring an additional 134 shares during the period. Finally, Financial Management Professionals Inc. grew its holdings in Merck & Co., Inc. by 4.7% during the second quarter. Financial Management Professionals Inc. now owns 3,035 shares of the company’s stock worth $236,000 after acquiring an additional 137 shares during the period. Institutional investors and hedge funds own 71.83% of the company’s stock.

MRK traded down $0.20 on Thursday, hitting $78.75. The company had a trading volume of 391,663 shares, compared to its average volume of 12,310,182. The company’s fifty day moving average price is $76.31 and its 200 day moving average price is $76.75. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $85.60. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06. The stock has a market cap of $199.35 billion, a price-to-earnings ratio of 36.08, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.31. The firm had revenue of $11.40 billion during the quarter, compared to analyst estimates of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same period in the previous year, the company earned $1.37 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.51 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 7th. Shareholders of record on Wednesday, September 15th were given a $0.65 dividend. This represents a $2.60 annualized dividend and a yield of 3.30%. The ex-dividend date was Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 43.77%.

A number of brokerages recently weighed in on MRK. Zacks Investment Research raised Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price target on the stock in a research note on Tuesday, August 24th. Morgan Stanley lifted their price target on Merck & Co., Inc. from $85.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Truist Securities assumed coverage on Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $76.79 price target on the stock. Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, October 1st. They set a “buy” rating and a $100.00 price target for the company. Finally, SVB Leerink lifted their price target on Merck & Co., Inc. from $101.00 to $104.00 and gave the company an “outperform” rating in a report on Monday, October 4th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $92.18.

About Merck & Co., Inc.

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.